Pharming Group (PHAR) Stock Statistics & Valuation Metrics

Pharming Group has a market cap or net worth of $706.68M. The enterprise value is $759.73M.

Pharming Group has 68,514,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pharming Group’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -3.21%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Pharming Group had revenue of 297.20M and earned -10.64M in profits. Earnings per share was -0.15.

In the last 12 months, operating cash flow was 6.13M and capital expenditures -996.65K, giving a free cash flow of 5.13M billion.

Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―

Pharming Group upcoming earnings date is Jul 31, 2025, Before Open (Confirmed).

Pharming Group as a current ratio of 3.91, with Debt / Equity ratio of 55.67%

In the past 12 months, Pharming Group has paid 2.43M in taxes.

Pharming Group EV to EBITDA ratio is 939.77, with an EV/FCF ratio of -2.61K.

Pharming Group has $107.27M in cash and marketable securities with $119.14M in debt, giving a net cash position of $11.87M billion.

Gross margin is 88.98%, with operating margin of -2.80%, and net profit margin of -3.58%.

The average price target for Pharming Group is $37.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy